HUTCHMED stock falls 2.75 percent despite new ESMO data

HUTCHMED stock was trading at USD 13.97 on Nasdaq on September 24, 2026, down 2.75 percent from the prior session and 14.82 percent below its 52-week high of USD 16.40. The company announced on September 23 that new and updated clinical data will be presented at the ESMO Congress 2026.

ESMO data broaden the pipeline

According to GlobeNewswire, the presentations will cover several compounds discovered by HUTCHMED. The ESMO Congress is scheduled for October 23 to October 27, 2026, in Madrid, with the program spanning oncology studies that could add clinical detail to the companys development pipeline.

The timing matters because HUTCHMED combines commercial products with late-stage and earlier research programs. Its portfolio includes fruquintinib, savolitinib and surufatinib, while the company continues to develop targeted therapies and immunotherapies for cancer and immunological diseases.

Oncology revenue outpaces total sales

HUTCHMEDs first-half 2026 results show a clear split between the overall business and oncology operations. According to FLCube, total consolidated revenue reached USD 278.0 million for the six months ended June 30, 2026, down 4 percent year over year at constant exchange rates. Oncology revenue, by contrast, rose 18 percent to USD 121.4 million, and oncology in-market sales increased 17 percent to USD 279.8 million.

The company reaffirmed full-year 2026 oncology and immunology consolidated revenue guidance of USD 330 million to USD 450 million. That range places execution in China and international markets at the center of the investment case, while the ESMO presentations offer a scheduled clinical checkpoint.

HUTCHMED stock stays below its high

At USD 13.97 on Nasdaq on September 24, 2026, HUTCHMED stock remained below the USD 16.40 52-week high, while its USD 2,438,176,716 market capitalization reflected the current value of the listed business.